BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1575 related articles for article (PubMed ID: 31424364)

  • 1. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
    Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
    Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linc00852 from cisplatin-resistant gastric cancer cell-derived exosomes regulates COMMD7 to promote cisplatin resistance of recipient cells through microRNA-514a-5p.
    Cao S; Fu B; Cai J; Zhang D; Wang C; Wu H
    Cell Biol Toxicol; 2023 Apr; 39(2):483-496. PubMed ID: 35088190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
    Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
    Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-Derived Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer Cells.
    Yao W; Guo P; Mu Q; Wang Y
    Cancer Biother Radiopharm; 2021 May; 36(4):347-359. PubMed ID: 32799541
    [No Abstract]   [Full Text] [Related]  

  • 7. DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP.
    Liu R; Zhang Y; Sun P; Wang C
    Open Biol; 2020 Apr; 10(4):190173. PubMed ID: 32343928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal lncRNA HEIH promotes cisplatin resistance in tongue squamous cell carcinoma via targeting miR-3619-5p/HDGF axis.
    Wang X; Yu H; Yu Z; Wang D
    Acta Histochem; 2020 Dec; 122(8):151647. PubMed ID: 33130420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.
    Yuwen DL; Sheng BB; Liu J; Wenyu W; Shu YQ
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2650-2658. PubMed ID: 28678319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
    Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L
    J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma.
    Zhang K; Shao CX; Zhu JD; Lv XL; Tu CY; Jiang C; Shang MJ
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32463473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis.
    Chen Z; Xu Z; Wang Q; Wang L; Zhang H; Wang W; Zhao H; Guo Y; Cui J
    Cell Cycle; 2023 Oct; 22(20):2211-2228. PubMed ID: 37974391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53.
    Jing X; Xie M; Ding K; Xu T; Fang Y; Ma P; Shu Y
    Clin Transl Med; 2022 May; 12(5):e780. PubMed ID: 35522909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer.
    Lin H; Zhang L; Zhang C; Liu P
    J Cell Mol Med; 2020 Aug; 24(16):8930-8941. PubMed ID: 32588541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1.
    Guo L; Zhu Y; Li L; Zhou S; Yin G; Yu G; Cui H
    Cancer Med; 2019 Sep; 8(12):5687-5701. PubMed ID: 31385464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.